Hyperfine (HYPR) Stock Forecast, Price Target & Predictions
HYPR Stock Forecast
Hyperfine stock forecast is as follows: an average price target of $1.60 (represents a 60.00% upside from HYPR’s last price of $1.00) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
HYPR Price Target
HYPR Analyst Ratings
Hyperfine Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Mar 22, 2024 | Larry Biegelsen | Wells Fargo | $1.60 | $1.01 | 58.42% | 60.00% |
Aug 11, 2022 | Larry Biegelsen | Wells Fargo | $2.40 | $1.50 | 60.00% | 140.00% |
Hyperfine Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $1.60 |
Last Closing Price | $1.00 | $1.00 | $1.00 |
Upside/Downside | -100.00% | -100.00% | 60.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 09, 2024 | B. Riley | Buy | Buy | Hold |
May 14, 2024 | Jefferies | - | Hold | Downgrade |
Oct 04, 2022 | B. Riley | - | Buy | Initialise |
Oct 03, 2022 | Prescience Point | - | Buy | Initialise |
Aug 11, 2022 | Wells Fargo | - | Overweight | Downgrade |
Hyperfine Financial Forecast
Hyperfine Revenue Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | $2.69M | $2.33M | $3.38M | $2.63M | $1.42M | $2.35M | - | $1.51M |
Avg Forecast | $4.04M | $3.30M | $3.26M | $3.05M | $3.71M | $2.95M | $3.20M | $2.07M | $2.50M | $1.70M | $2.00M | $1.00M |
High Forecast | $4.27M | $3.38M | $3.45M | $3.23M | $3.75M | $3.12M | $3.38M | $2.19M | $2.64M | $1.80M | $2.00M | $1.00M |
Low Forecast | $3.79M | $3.20M | $3.07M | $2.87M | $3.67M | $2.77M | $3.01M | $1.94M | $2.35M | $1.60M | $2.00M | $1.00M |
# Analysts | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - |
Surprise % | - | - | - | - | 0.72% | 0.79% | 1.06% | 1.28% | 0.57% | 1.38% | - | 1.51% |
Hyperfine EBITDA Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - |
EBITDA | - | - | - | - | $-11.63M | $-11.76M | $-11.43M | $-12.78M | $-13.37M | $-13.04M | - | $-23.52M |
Avg Forecast | $-2.42M | $-1.98M | $-1.96M | $-1.83M | $-2.22M | $-1.77M | $-1.92M | $-1.24M | $-1.50M | $-1.02M | $-1.20M | $-9.86M |
High Forecast | $-2.28M | $-1.92M | $-1.84M | $-1.72M | $-2.20M | $-1.66M | $-1.80M | $-1.16M | $-1.41M | $-958.18K | $-1.20M | $-7.89M |
Low Forecast | $-2.56M | $-2.03M | $-2.07M | $-1.94M | $-2.25M | $-1.87M | $-2.03M | $-1.31M | $-1.59M | $-1.08M | $-1.20M | $-11.83M |
Surprise % | - | - | - | - | 5.23% | 6.64% | 5.95% | 10.31% | 8.91% | 12.79% | - | 2.39% |
Hyperfine Net Income Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - |
Net Income | - | - | - | - | $-10.68M | $-10.76M | $-10.64M | $-11.29M | $-12.69M | $-12.89M | - | $-23.78M |
Avg Forecast | $-10.81M | $-10.09M | $-10.09M | $-10.57M | $-13.03M | $-12.01M | $-12.25M | $-9.37M | $-15.81M | $-18.49M | $-21.58M | $-9.96M |
High Forecast | $-9.95M | $-9.29M | $-9.29M | $-9.73M | $-12.26M | $-11.06M | $-11.28M | $-8.63M | $-14.56M | $-17.03M | $-21.58M | $-7.97M |
Low Forecast | $-11.62M | $-10.84M | $-10.84M | $-11.36M | $-13.79M | $-12.91M | $-13.16M | $-10.07M | $-16.99M | $-19.87M | $-21.58M | $-11.96M |
Surprise % | - | - | - | - | 0.82% | 0.90% | 0.87% | 1.20% | 0.80% | 0.70% | - | 2.39% |
Hyperfine SG&A Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - |
SG&A | - | - | - | - | $6.70M | $7.14M | $7.80M | $8.73M | $8.71M | $6.63M | - | $15.52M |
Avg Forecast | $52.11M | $42.56M | $42.13M | $39.42M | $47.85M | $38.08M | $41.31M | $26.68M | $32.27M | $21.95M | $25.82M | $15.45M |
High Forecast | $55.11M | $43.68M | $44.55M | $41.69M | $48.37M | $40.27M | $43.69M | $28.22M | $34.13M | $23.21M | $25.82M | $15.45M |
Low Forecast | $48.95M | $41.31M | $39.57M | $37.03M | $47.33M | $35.77M | $38.81M | $25.06M | $30.32M | $20.62M | $25.82M | $15.45M |
Surprise % | - | - | - | - | 0.14% | 0.19% | 0.19% | 0.33% | 0.27% | 0.30% | - | 1.00% |
Hyperfine EPS Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - |
EPS | - | - | - | - | $-0.15 | $-0.15 | $-0.15 | $-0.16 | $-0.18 | $-0.18 | - | $-0.34 |
Avg Forecast | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.18 | $-0.17 | $-0.17 | $-0.13 | $-0.22 | $-0.26 | $-0.30 | $-0.21 |
High Forecast | $-0.14 | $-0.13 | $-0.13 | $-0.14 | $-0.17 | $-0.15 | $-0.16 | $-0.12 | $-0.20 | $-0.24 | $-0.30 | $-0.21 |
Low Forecast | $-0.16 | $-0.15 | $-0.15 | $-0.16 | $-0.19 | $-0.18 | $-0.18 | $-0.14 | $-0.24 | $-0.28 | $-0.30 | $-0.21 |
Surprise % | - | - | - | - | 0.83% | 0.90% | 0.88% | 1.23% | 0.82% | 0.70% | - | 1.62% |
Hyperfine Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
APYX | Apyx Medical | $1.08 | $8.50 | 687.04% | Buy |
INGN | Inogen | $10.84 | $26.00 | 139.85% | Buy |
OFIX | Orthofix Medical | $16.22 | $31.00 | 91.12% | - |
NPCE | NeuroPace | $6.96 | $12.88 | 85.06% | Buy |
HYPR | Hyperfine | $1.00 | $1.60 | 60.00% | Buy |
LUNG | Pulmonx | $8.18 | $12.25 | 49.76% | Buy |
LIVN | LivaNova | $51.00 | $70.20 | 37.65% | Buy |
KIDS | OrthoPediatrics | $31.08 | $40.80 | 31.27% | Buy |
IRMD | IRadimed | $48.63 | $60.00 | 23.38% | Buy |
ITGR | Integer | $126.12 | $131.00 | 3.87% | Buy |
SRDX | Surmodics | $39.26 | $39.50 | 0.61% | Buy |
HYPR Forecast FAQ
Is Hyperfine a good buy?
Yes, according to 4 Wall Street analysts, Hyperfine (HYPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of HYPR's total ratings.
What is HYPR's price target?
Hyperfine (HYPR) average price target is $1.6 with a range of $1.6 to $1.6, implying a 60.00% from its last price of $1. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Hyperfine stock go up soon?
According to Wall Street analysts' prediction for HYPR stock, the company can go up by 60.00% (from the last price of $1 to the average price target of $1.6), up by 60.00% based on the highest stock price target, and up by 60.00% based on the lowest stock price target.
Can Hyperfine stock reach $2?
HYPR's average twelve months analyst stock price target of $1.6 does not support the claim that Hyperfine can reach $2 in the near future.
What are Hyperfine's analysts' financial forecasts?
HYPR's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $13.65M (high $14.33M, low $12.93M), average EBITDA is $-8.19M (high $-7.755M, low $-8.6M), average net income is $-41.544M (high $-38.271M, low $-44.654M), average SG&A $176.21M (high $185.03M, low $166.86M), and average EPS is $-0.577 (high $-0.531, low $-0.62).
Did the HYPR's actual financial results beat the analysts' financial forecasts?
Based on Hyperfine's last annual report (Dec 2023), the company's revenue was $11.03M, which missed the average analysts forecast of $11.92M by -7.48%. Apple's EBITDA was $-48.115M, beating the average prediction of $-7.154M by 572.56%. The company's net income was $-44.238M, missing the average estimation of $-46.647M by -5.17%. Apple's SG&A was $30.38M, missing the average forecast of $153.92M by -80.26%. Lastly, the company's EPS was $-0.62, missing the average prediction of $-0.648 by -4.25%. In terms of the last quarterly report (Dec 2023), Hyperfine's revenue was $2.69M, missing the average analysts' forecast of $3.71M by -27.54%. The company's EBITDA was $-11.629M, beating the average prediction of $-2.224M by 422.89%. Hyperfine's net income was $-10.684M, missing the average estimation of $-13.028M by -17.99%. The company's SG&A was $6.7M, missing the average forecast of $47.85M by -86.00%. Lastly, the company's EPS was $-0.15, missing the average prediction of $-0.181 by -17.05%